Cognivia, a Mont-Saint-Guibert, Belgium-based AI company dedicated to reshaping pharmaceutical and biotech clinical research through cutting-edge AI-ML algorithms, has raised €15.5 million in funding.
Investors
The strategic investments were from Vesalius Biocapital IV, SFPIM (Société Fédérale de Participations et d'Investissement), and WE (Wallonie Entreprendre).
Cognivia Use of Funds
This infusion of capital will enable Cognivia to deploy its predictive clinical trial solutions, accelerate drug development, and introduce groundbreaking approaches to enhancing outcomes for patients and stakeholders worldwide.
About Cognivia
Founded in 2013, Cognivia is a company that combines quantification of patient psychology with AI/ML to improve the measurement of therapeutic efficacy in clinical trials – and beyond. Its technologies predict patient behavior and treatment response in clinical trials using predictive ML-powered algorithms based on a quantitative understanding of patient psychological traits, expectations, and beliefs collected via its own and specific questionnaires developed toward that objective. The company's mission is to "quantify the power of the mind" to optimize and accelerate drug development programs.
Funding Details
Company: Cognivia
Raised: €15.5M
Round: Unknown
Funding Month: April 2024
Investors: Vesalius Biocapital IV, SFPIM, WE
Company Website: https://cognivia.com/
Software Category: Clinical Trial Technology Solutions
Source: https://www.prnewswire.com/news-releases/cognivia-secures-strategic-15-5m-funding-to-empower-drug-development-with-ai-ml-solutions-302120140.html